RT Journal Article
T1 Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.
A1 Carral San Laureano, Florentino
A1 Tomé Fernández-Ladreda, Mariana
A1 Jiménez Millán, Ana Isabel
A1 García Calzado, Concepción
A1 Ayala Ortega, María Del Carmen
K1 diabetes mellitus
K1 insulin
AB There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.
YR 2021
FD 2021-03-26
LK https://hdl.handle.net/10668/25152
UL https://hdl.handle.net/10668/25152
LA en
DS RISalud
RD Apr 19, 2025